RISK WATCHYahoo • 3d ago
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key InsightsGinkgo Bioworks Holdings, Inc. (DNA) closed at $12.74 in the latest trading session, marking a -4.35% move from the prior day.
Why DNA Stock dropped -4.35% Today — RQD Quant Desk Flash
$12.74 -4.35% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.62
Ginkgo Bioworks Holdings Inc. (Class A) (DNA) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $819.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DNA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $12.74 (-4.35% 1D, market cap $819.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DNA ranks #964 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DNA compare to SANA and GLUE in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANA (Sana Biotechnology Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $814.3M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DNA?
▼
Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.62 (-0.97%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DNA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY DNA SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+7/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$13.00-21% Next Q
36
Q2 (-2Q)Grade E$10.27-2.7% Next Q
33
Q3 (-1Q)Grade E$9.99+27.5% Next Q
31
CurrentGrade E$12.74-10% Hist 90D α
28
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DNA Turnaround Squeeze
While DNA currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.55) and Max Pain ($13.38) forces dealer call-delta covering toward $19.13.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DNA Stock dropped -4.35% Today — RQD Quant Desk Flash
Ginkgo Bioworks Holdings Inc. (Class A) (DNA) dropped -4.35% to $12.74, trading at 57% of its 52-week range ($5.37 – $18.22). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 57% of its 52-week range ($5.37 – $18.22) with RSI-14 at 52 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $12.74 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live DNA Headlines & Catalysts
RISK WATCHYahoo • 8d ago
What Ginkgo Bioworks Bears Saw Before The FallGinkgo Bioworks has just agreed to open its Boston autonomous lab to National Science Foundation X-Labs teams, while also wiring Araceli’s high-speed imaging gear into its Nebula setup. For Ginkgo Bioworks shareholders,
CATALYSTFintel • 9d ago
Ginkgo Bioworks Holdings Consensus Price Target Raised 14.29% to $8.16RISK WATCHYahoo • 12d ago
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to KnowGinkgo Bioworks Holdings, Inc. (DNA) reached $9.86 at the closing of the latest trading day, reflecting a -2.09% change compared to its last close.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DNA)
- ✓Walkthrough of DNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +50.59%📐 HORIZONTAL RANGE
2026-10-30O $12.12H $12.74L $10.60C $12.74VOL 2.73M
RES: $19.53SUP: $5.94SMA50: $9.55SMA200: $8.59
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DNA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DNA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DNA)
Health Care Rank #964 of 1016
⚔️ SANA vs DNA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DNA vs. SANA, GLUE, MGTX, PRME)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Ginkgo Bioworks Holdings Inc. (Class A) (DNA) ranks #964 by composite RQD confidence (28/100, grade E) and #383 by equity capitalization ($819.7M). Within this direct 5-issuer industry benchmark cohort, DNA leads on earnings valuation at N/A trailing P/E, while DNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SANA currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DNA at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DNA
ACTIVE
Ginkgo Bioworks Holdings Inc. (Class A) | E | 28/100 | — | — | -35.0% | -4.35% | $819.7M | Benchmark Subject |
| SANA Sana Biotechnology Inc. | D | 46/100 | — | — | -35.0% | +3.42% | $814.3M | /sana-vs-dna → |
| GLUE Monte Rosa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +0.18% | $927.4M | /glue-vs-dna → |
| MGTX MeiraGTx Holdings plc | E | 27/100 | — | — | -35.0% | -0.46% | $932.1M | /mgtx-vs-dna → |
| PRME Prime Medicine Inc. | E | 21/100 | — | — | -35.0% | -2.24% | $950.4M | /prme-vs-dna → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001830214In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ginkgo Bioworks Holdings Inc. (Class A) (DNA) reported GAAP revenue of $170.2M (-25.1% vs. FY2024 revenue of $227.0M , and -32.3% cumulative change since FY2023) , GAAP net income of -$313.0K, operating cash flow of -$171.1M, and free cash flow of -$178.7M (+53.2% YoY). On the balance sheet, DNA closed FY2025 with $1.12B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.2M | -$313.0K | -$171.1M | -$178.7M | $1.12B | — |
| FY2024 (FY) | 2024-12-31 | $227.0M | -$547.0K | -$319.6M | -$382.1M | $1.38B | — |
| FY2023 (FY) | 2023-12-31 | $251.5M | -$893.0K | -$295.5M | -$295.5M | — | — |
3. DNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $12.74 (-4.35% 1D, market cap $819.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DNA ranks #964 in composite RQD confidence.
How does DNA compare to SANA and GLUE in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANA (Sana Biotechnology Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $814.3M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DNA?
Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DNA trading relative to its 50-day, 200-day, and 52-week technical levels?
DNA last traded at $12.74 (-4.35% on volume of 2,897,891 shares), positioning the stock +33.40% above its 50-day simple moving average ($9.55) and +48.31% above its 200-day simple moving average ($8.59). Across its 52-week range of $5.37 to $18.22, DNA sits at the 57.4% percentile with a 14-day RSI of 52.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.15 to $14.33).
DNA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is DNA stock moving today?
Why DNA Stock dropped -4.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.